chs 828 has been researched along with terbutaline in 1 studies
| Studies (chs 828) | Trials (chs 828) | Recent Studies (post-2010) (chs 828) | Studies (terbutaline) | Trials (terbutaline) | Recent Studies (post-2010) (terbutaline) |
|---|---|---|---|---|---|
| 21 | 0 | 17 | 3,216 | 844 | 322 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alisi, MA; Aprile, S; Clemente, N; Colombo, G; Galli, U; Genazzani, AA; Grosa, G; Mattoteia, D; Polenzani, L; Scanziani, E; Terrazzino, S; Travelli, C; Tron, GC | 1 |
1 other study(ies) available for chs 828 and terbutaline
| Article | Year |
|---|---|
Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
Topics: Animals; Cell Line, Tumor; Click Chemistry; Cytokines; Enzyme Inhibitors; Humans; Mice; Neoplasms; Nicotinamide Phosphoribosyltransferase; Triazoles | 2019 |